{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:05:19Z","timestamp":1784721919666,"version":"3.55.0"},"reference-count":57,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Acute myeloid leukemia (AML) is characterized not only by its heterogeneity but also by its high relapse rate. This results in limited treatment options, especially in elderly or therapy-refractory patients. It is known that inhibiting anti-apoptotic BCL-2 family proteins can be effective; however, cellular resistance mechanisms often limit the efficacy of this treatment. We studied the effects of the BCL-2 inhibitor ABT-737, the MCL-1 inhibitor S63845, and their combination on AML cell lines and primary AML patient cells. Materials and Methods: To analyze the effects of ABT-737 and S63845 treatment on cells, cell energy phenotype, apoptosis, and cell cycle were assessed, and gene expression by RT-qPCR and protein levels by Western blot analysis were measured. Results: Treatment with the BCL-2 inhibitor ABT-737, the MCL-1 inhibitor S63845, and their combination reduced AML cell viability and induced apoptosis. Dual treatment also altered the expression of epigenetic regulators, as the levels of DNMT1, EZH2, SUZ12, and HDAC1 were reduced, while histone acetylation was increased. An increase in pro-apoptotic markers (PARP cleavage, caspase-9) was observed, and the expression of oncogenes (MYC, WT1) was reduced in model cell lines and primary AML patient cells. Conclusions: BCL-2 and MCL-1 inhibition, alone or in combination, induced apoptosis and altered the expression of epigenetic regulators and oncogenes in AML cell lines and primary patient cells, with no consistent advantage of combined treatment over single agents. BCL-2\/MCL-1 inhibition remains a promising approach for AML, and further work should clarify which patients or disease subtypes are most likely to benefit from combined versus single-agent treatment.<\/jats:p>","DOI":"10.3390\/medicina62071425","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:48:28Z","timestamp":1784717308000},"page":"1425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of BCL-2 and MCL-1 Inhibition on Apoptotic and Transcriptional Profiles in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-666X","authenticated-orcid":false,"given":"Giedr\u0117","family":"Skliut\u0117","sequence":"first","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Saul\u0117tekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigint\u0117","family":"Kuklyt\u0117","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Saul\u0117tekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrius","family":"\u017du\u010denka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6077-0136","authenticated-orcid":false,"given":"Veronika Viktorija","family":"Borutinskait\u0117","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Saul\u0117tekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-9439","authenticated-orcid":false,"given":"R\u016bta","family":"Navakauskien\u0117","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Saul\u0117tekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and Relevance of Human Acute Myeloid Leukemia Stem Cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fleischmann, M., Schnetzke, U., Hochhaus, A., and Scholl, S. (2021). Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13225722"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute Myeloid Leukemia: Current Progress and Future Directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alvanidis, G., Kotsos, D., Frouzaki, C., Fola, A., and Hatjiharissi, E. (2025). The Potential Role of BCL-2 Inhibition in Amyloidosis and Plasma Cell Leukemia. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1549891"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance Therapy for FLT3-ITD-Mutated Acute Myeloid Leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108848","DOI":"10.1016\/j.pharmthera.2025.108848","article-title":"Investigation into Biased Signaling, Glycosylation, and Drug Vulnerability of Acute Myeloid Leukemia","volume":"270","author":"Pienkowski","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib Induces Deep Durable Remissions in Patients with Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"George, B., Kantarjian, H., Baran, N., Krocker, J.D., and Rios, A. (2021). TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910782"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia","volume":"27","author":"Atilla","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 Is a Novel Target for CAR T-Cell Therapy in Acute Myeloid Leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2025.03.052","article-title":"CAR T Cell Therapy for Treatment of Acute Myeloid Leukemia, Advances and Outcomes","volume":"33","author":"Khalifeh","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting Multiple Signaling Pathways: The New Approach to Acute Myeloid Leukemia Therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: Prognostic and Therapeutic Implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Valiulien\u0117, G., Vitkevi\u010dien\u0117, A., Skliut\u0117, G., Borutinskait\u0117, V., and Navakauskien\u0117, R. (2021). Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling. Molecules, 26.","DOI":"10.3390\/molecules26082303"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Opydo, M., Mlyczy\u0144ska, A., Mlyczy\u0144ska, E., Rak, A., and Kolaczkowska, E. (2023). Synergistic Action of MCL-1 Inhibitor with BCL-2\/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087180"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/s41418-018-0244-y","article-title":"By Reducing Global mRNA Translation in Several Ways, 2-Deoxyglucose Lowers MCL-1 Protein and Sensitizes Hemopoietic Tumor Cells to BH3 Mimetic ABT737","volume":"26","author":"Tailler","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/14728222.2013.733001","article-title":"Targeting the Bcl-2 Family for Cancer Therapy","volume":"17","author":"Thomas","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 Inhibitor S63845 Is Tolerable and Effective in Diverse Cancer Models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Skopek, R., Palusi\u0144ska, M., Kaczor-Keller, K., Pingwara, R., Papierniak-Wygl\u0105da\u0142a, A., Schenk, T., Lewicki, S., Zelent, A., and Szyma\u0144ski, \u0141. (2023). Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065377"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Borutinskait\u0117, V., \u017du\u010denka, A., Vitkevi\u010dien\u0117, A., Sto\u0161kus, M., Kaupinis, A., Valius, M., Gineikien\u0117, E., and Navakauskien\u0117, R. (2022). Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.821676"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vitkevi\u010dien\u0117, A., Skliut\u0117, G., \u017du\u010denka, A., Borutinskait\u0117, V., and Navakauskien\u0117, R. (2022). Potential Prognostic Markers for Relapsed\/Refractory vs. Responsive Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14112752"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108122","DOI":"10.1016\/j.leukres.2025.108122","article-title":"Exosomal miR-140\u20133p Produced by Bone Marrow Stromal Cells Affects Acute Myeloid Leukemia Cell Growth and Apoptosis by Targeting SUZ12","volume":"159","author":"Li","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105339","DOI":"10.1016\/j.exphem.2025.105339","article-title":"Polycomb Repressive Complexes as Therapeutic Targets in Hematologic Malignancies","volume":"155","author":"Yamagishi","year":"2026","journal-title":"Exp. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.1202258109","article-title":"Polycomb Repressive Complex 2 Is Required for MLL-AF9 Leukemia","volume":"109","author":"Neff","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating Mutations of the Histone Methyltransferase Gene EZH2 in Myeloid Disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/03008916251346563","article-title":"Effect of the IDH1 Inhibitor Combined with Hypomethylating Agents on Acute Myeloid Leukemia","volume":"111","author":"Cheng","year":"2025","journal-title":"Tumori"},{"key":"ref_29","first-page":"653","article-title":"Knocking Out DNMT1 Enhances the Inhibitory Effect of NK Cells on Acute Myeloid Leukemia","volume":"33","author":"Wu","year":"2025","journal-title":"Zhongguo Shi Yan Xue YE Xue ZA Zhi"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41375-025-02799-w","article-title":"The Splicing Factor PTBP1 Interacts with RUNX1 and Is Required for Leukemia Cell Survival","volume":"40","author":"Dhir","year":"2026","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"118574","DOI":"10.1016\/j.ejmech.2026.118574","article-title":"Discovery of Novel Aminopyrimidine-Hydroxamate Derivatives as Dual FLT3\/HDAC Inhibitors: Design, Synthesis, and Anti-Hematologic Malignancy Evaluation","volume":"305","author":"Ran","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3892\/or.2025.9005","article-title":"Targeting Cell Death Pathways in Acute Myeloid Leukemia: Molecular Mechanisms and Clinical Implications (Review)","volume":"54","author":"Jianati","year":"2025","journal-title":"Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 Inhibition in AML: An Unexpected Bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Algar\u00edn, E.M., Quwaider, D., Campos-Laborie, F.J., D\u00edaz-Tejedor, A., Mogoll\u00f3n, P., Vuelta, E., Mart\u00edn-S\u00e1nchez, M., San-Segundo, L., Gonz\u00e1lez-M\u00e9ndez, L., and Guti\u00e9rrez, N.C. (2021). Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. Cells, 10.","DOI":"10.3390\/cells10030559"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-21-0511","article-title":"Anti-Apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-Negative Diffuse Large B-Cell Lymphomas","volume":"21","author":"Klanova","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.18632\/oncotarget.6405","article-title":"Bcl-2 Family Proteins as Regulators of Cancer Cell Invasion and Metastasis: A Review Focusing on Mitochondrial Respiration and Reactive Oxygen Species","volume":"7","author":"Um","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1084\/jem.189.11.1815","article-title":"Dephosphorylation Targets Bcl-2 for Ubiquitin-Dependent Degradation: A Link between the Apoptosome and the Proteasome Pathway","volume":"189","author":"Dimmeler","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.celrep.2017.09.052","article-title":"Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis","volume":"21","author":"Edison","year":"2017","journal-title":"Cell Rep."},{"key":"ref_39","first-page":"33","article-title":"Ubiquitin-Proteasome Pathway-Mediated Regulation of the Bcl-2 Family: Effects and Therapeutic Approaches","volume":"109","author":"Tang","year":"2023","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 Induce Apoptosis by Targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cui, J., and Placzek, W.J. (2018). Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010308"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/cdd.2011.28","article-title":"MiR-148a Promotes Apoptosis by Targeting Bcl-2 in Colorectal Cancer","volume":"18","author":"Zhang","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molcel.2015.01.018","article-title":"Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death","volume":"57","author":"Ichim","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","article-title":"Sublethal Cytochrome c Release Generates Drug-Tolerant Persister Cells","volume":"185","author":"Kalkavan","year":"2022","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.gastro.2019.05.057","article-title":"Intestinal PPAR\u03b1 Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6","volume":"157","author":"Luo","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-020-00526-4","article-title":"DNMT1 as a Therapeutic Target in Pancreatic Cancer: Mechanisms and Clinical Implications","volume":"43","author":"Wong","year":"2020","journal-title":"Cell. Oncol."},{"key":"ref_47","first-page":"5275","article-title":"Increased EZH2 Expression during the Adenoma-Carcinoma Sequence in Colorectal Cancer","volume":"16","author":"Ohuchi","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/cdd.2013.88","article-title":"Epigenetic Silencing of Bim Transcription by Spi-1\/PU.1 Promotes Apoptosis Resistance in Leukaemia","volume":"20","author":"Evanno","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.V77.5.1080.1080","article-title":"NB4, a Maturation Inducible Cell Line with t(15;17) Marker Isolated from a Human Acute Promyelocytic Leukemia (M3)","volume":"77","author":"Lanotte","year":"1991","journal-title":"Blood"},{"key":"ref_51","first-page":"1173","article-title":"Distinct Apoptotic Responses in Maturation Sensitive and Resistant t(15;17) Acute Promyelocytic Leukemia NB4 Cells. 9-Cis Retinoic Acid Induces Apoptosis Independent of Maturation and Bcl-2 Expression","volume":"9","author":"Bruel","year":"1995","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.leu.2401419","article-title":"In Acute Promyelocytic Leukemia NB4 Cells, the Synthetic Retinoid CD437 Induces Contemporaneously Apoptosis, a Caspase-3-Mediated Degradation of PML\/RARalpha Protein and the PML Retargeting on PML-Nuclear Bodies","volume":"13","year":"1999","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V56.3.344.344","article-title":"Human Myeloid Leukemia Cell Lines: A Review","volume":"56","author":"Koeffler","year":"1980","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V56.2.265.265","article-title":"An Undifferentiated Variant Derived from the Human Acute Myelogenous Leukemia Cell Line (KG-1)","volume":"56","author":"Koeffler","year":"1980","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/ol.2012.709","article-title":"The Importance of Molecular Cytogenetic Analysis Prior to Using Cell Lines in Research: The Case of the KG-1a Leukemia Cell Line","volume":"4","author":"Pelliccia","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-016-0327-5","article-title":"Alantolactone Selectively Ablates Acute Myeloid Leukemia Stem and Progenitor Cells","volume":"9","author":"Ding","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41467-020-20378-8","article-title":"BRD4-Mediated Repression of P53 Is a Target for Combination Therapy in AML","volume":"12","author":"Latif","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:53:08Z","timestamp":1784721188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071425"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071425","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}